What investors will watch in Novo's ObesityWeek data: pill persistence and switching
Newsquawk notes that markets usually react to the data itself rather than conference announcements, and that real-world pill data will be read for uptake, discontinuation and switching between brands. Persistence has historically been the weak spot for oral weight-loss medicines compared with injections.
Source: Newsquawk (29 Oct 2026). Image: Newsquawk.